The University of Chicago Medicine Comprehensive Cancer Center, Chicago
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
UChicago Medicine Orland Park, Orland Park

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT05868226

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Northwestern Medicine Chicago Proton Center, Warrenville

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 50 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT01766297

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

The University of Chicago Medicine Comprehensive Cancer Center, Chicago

ተሳታዮችን በመፈለግ ላይ

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07553234

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Rush University Medical Center ( Site 0079), Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

City of Hope Chicago, Zion

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Peoria
Clinical Trial Site, Urbana

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Northwestern University, Chicago

ተሳታዮችን በመፈለግ ላይ

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

City of Hope, Chicago, Chicago
Northwestern Memorial Hospital, Chicago
University of Illinois at Chicago, Chicago
እና 3 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07174336

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of Chicago, Chicago

ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ30 እስከ 74 · ሴቶች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT02620852

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Cancer Care Specialists, Decatur
Cancer Care Specialists of Illinois, O'Fallon
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

City of Hope, Chicago, Zion

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07109726

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University of Illinois Hospital & Health Sciences System, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Illinois Cancer Specialists, Arlington Heights
Northwestern Memorial Hospital, Chicago
RUSH MD Anderson Cancer Center, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT06492616

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Orchard Healthcare Research Inc., Skokie

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT05935384

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope® Cancer Center Chicago, Zion

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT03424005

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Orchard Healthcare Research Inc. ( Site 0006), Skokie

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT06797635

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

University of Illinois Cancer Center, Chicago
University of Chicago Medicine, Chicago
City of Hope - Chicago, Zion

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Chicago, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Carle Cancer Center, Urbana

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05386108

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

NorthShore University Health System - Evanston Hospital, Evanston
NorthShore University HealthSystem - Evanston Hospital, Evanston
Duly Health and Care, Lisle
እና 2 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ ከ18 እስከ 55 · ሴቶች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07310420

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Evanston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ ከ18 እስከ 130 · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

City of Hope® Cancer Center Chicago, Zion

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Northwestern University, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT05315700

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Northwestern University, Chicago
Rush University Medical Center, Chicago
University of Chicago, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT06062498

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Rush University Medical Center, Chicago
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Southern Illinois Hospital Services, Carbondale
Cancer Care Specialist of Illinois, O'Fallon

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ ከ18 እስከ 99 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT07211178

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

University of Illinois Cancer Center, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04886531

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Cancer Care Specialists of Central Illinois, O'Fallon
Springfield Clinic, Springfield
Carle Cancer Center, Urbana
እና 1 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

OSF Saint Anthony's Health Center, Alton
Advocate Outpatient Center - Aurora, Aurora
Advocate Good Shepherd Hospital, Barrington
እና 83 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ ከ18 እስከ 60 · ሴቶች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Northwestern University, Chicago
Southern Illinois University-Simmons, Springfield
Carle Foundation Cancer Institute-Urbana, Urbana

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06072612

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

University Of Chicago Medicine Comprehensive Cancer Center, Chicago

ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ

እድሜ 25 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT03729115

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

University of Chicago Medical Center, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06533826

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT06764940

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois, Chicago

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT06441890

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።